FIELD: biotechnology.
SUBSTANCE: present invention relates to immunology. Disclosed are full-size anti-CD40 agonist antibodies, as well as anti-CD40 antibodies.
EFFECT: present invention can find further application in detecting CD40 and suppressing activity of CD40.
17 cl, 37 dwg, 25 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
